SLC6A3 and Tourette syndrome: Reduced tonic extracellular3, increased presynaptic4, and pharmacologically released intrasynaptic dopamine contents5 as well as increased dopamine receptor availability6, suggests an overactive dopamine transporter (DAT)7, 8 in repetitive disorders, including Tourette syndrome (TS).